Yufeng Li

Yufeng Li

Auto-generated profile, based on publicly available information

Yufeng Li

State Key Laboratory of Drug Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Shanghai, 201203, P. R. China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
YLYuting Lu
Yuting Lu
JXJunyu Xu
Junyu Xu
YLYufeng Li
Yufeng Li
RWRuoran Wang
Ruoran Wang
CDChengqiu Dai
Chengqiu Dai
JLJingya Li
Jingya Li
Impeded autophagy can impair pancreatic β cell function by causing apoptosis, of which DAP-related apoptosis-inducing kinase-2 (DRAK2) is a critical regulator. Here, we identified a marked up-regulation of DRAK2 in pancreatic tissue across humans, macaques, and mice with type 2 diabetes (T2D). Further studies in mice showed that conditional knockout (cKO) of DRAK2 in pancreatic β cells protected β cell function against high-fat diet feeding along with sustained autophagy and mitochondrial function. Phosphoproteome analysis in isolated mouse primary islets revealed that DRAK2 directly phosphorylated unc-51–like autophagy activating kinase 1 (ULK1) at Ser 56 , which was subsequently found to induce ULK1 ubiquitylation and suppress autophagy. ULK1-S56A mutation or pharmacological inhibition of DRAK2 preserved mitochondrial function and insulin secretion against lipotoxicity in mouse primary islets, Min6 cells, or INS-1E cells. In conclusion, these findings together indicate an indispensable role of the DRAK2-ULK1 axis in pancreatic β cells upon metabolic challenge, which offers a potential target to protect β cell function in T2D.

30 August 2019 in Diabetes
Verified
Journal Article
Open access
PDF file
HJHaowen Jiang
Haowen Jiang
JJJia Jin
Jia Jin
YDYanan Duan
Yanan Duan
ZXZhifu Xie
Zhifu Xie
YLYufeng Li
Yufeng Li
JLJia Li
Jia Li
Uncoupling of mitochondrial respiration by chemical uncouplers has proven effective in ameliorating obesity, insulin resistance, and hyperglycemia. However, development of uncoupler-based therapy remains challenging due to its potentially lethal adverse effects. Here, we identify pyruvate dehydrogenase (PDH) as a key modifier of the toxicity profile of 2, 4-dinitrophenol (DNP), a prototypical mitochondrial uncoupler. PDH activation by dichloroacetic acid (DCA) protects mice from DNP-induced hyperlactacidemia, hyperthermia, and death while preserving the ability of DNP to promote fuel oxidation and improve insulin sensitivity in mice. Mechanistically, PDH activation switches on mitochondrial glucose oxidation to accommodate increased glycolytic flux, leading to reduced lactate secretion during uncoupler treatments. We devised a chemical screening strategy and discovered compound 6j as a dual-action compound that simultaneously activates PDH and uncouples mitochondrial respiration. Compound 6j exhibits an excellent efficacy and safety profile in restoring glucose homeostasis in diabetic mice. This work establishes a new principle to safely harness the power of chemical uncouplers for the treatment of metabolic disease.

20 September 2006 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ESEiko Sugiyama
Eiko Sugiyama
Naoki TanakaNaoki Tanaka
Naoki Tanaka
TNTamie Nakajima
Tamie Nakajima
Yuji KamijoYuji Kamijo
Yuji Kamijo
SYShin Yokoyama
Shin Yokoyama
TAToshifumi Aoyama
Toshifumi Aoyama